Home' Australian Pharmacist : Australian Pharmacist March 2014 Contents Australian Pharmacist March 2014 I ©Pharmaceutical Society of Australia Ltd. 79
Better business practice
Better customer service
Better sta training
Better be part of Self Care!
PSA's popular Self Care Fact Cards
are now available electronically on
your PC, laptop or tablet.
Enhance your customer loyalty and engagement
» 100 common topics for pharmacy
» Discuss with your customers in store
» Email to your customers
» Print for your customers
Try before you buy. Experience how these resources can boost your customer service.
Sign up for a FREE one month demo today!*
PSA Your voice.
www.psa.org.au/selfcare email@example.com 1300 369 772
*demo allows access to a sample of eFactCards for: Acne, Children's pain and fever, Asthma medicines, Diabetes type 2, Headlice, Headache
Sano Consumer Healthcare
Recoverlyte, from the makers of Gastrolyte,
is an Australian-first formulation which
features a four-way blend of electrolytes,
vitamins, minerals and amino acids to
help the body recover from a late night
out. Recoverlyte is a tropical flavoured
effervescent powder designed to restore
the body's natural balance and provide
a much needed energy boost when a
late night involves lack of sleep, alcohol
or vigorous activity, such as dancing.
The product launch follows consumer
research which suggests that following
a late night out, a third (33%) of Aussies
opt to remain in bed or motionless on
the couch while more than a fifth (22%)
ditch the healthy diet in favour of calorie
laden food. According to the Recoverlyte
research, of these top recovery rituals,
which include rest and slumber, and
greasy food, more than half of Australians
surveyed said they only sometimes
worked, if at all.
Pharmacists will be supported with in
store point of sale, including a specific
branded counter display unit. Recoverlyte
is available in pharmacies and now.
ViiV Healthcare Australia
Tivicay (dolutegravir), an integrase
inhibitor has been approved by the
Therapeutic Goods Administration (TGA)
for the treatment of HIV infection in
combination with other antiretroviral
agents in adults and children >12 years
of age and weighing ≥ 40 kg.
Professor Andrew Carr from St Vincent's
Hospital in Sydney said: 'Dolutegravir
has a strong efficacy profile, good
tolerability, once-daily dosing for
the majority of patients, a low rate of
drug interactions and few metabolic
complications. It provides an important
option for Australians who are starting
treatment or have failed other therapies'.
In clinical trials, the most common
adverse reactions of Grade 2--4 and
greater than 2% frequency in treatment
naïve pivotal trials were insomnia and
headache (once daily dolutegravir).
In integrase resistant patients, diarrhoea
and headache were the most common
adverse reactions (dolutegravir
Xifaxan 550 (rifaximin) was PBS listed in
December 2013. Xifaxan 550 is indicated for
the preventing the recurrence of hepatic
encephalopathy where other treatments
have failed or are contraindicated. Hepatic
encephalopathy (HE) is a deterioration of
brain function that occurs when the liver is
no longer able to remove toxic substances
from the blood. It is commonly caused by
diseases that reduce liver function such
as hepatitis and cirrhosis. Symptoms of
severe HE include disorientation, confusion,
inappropriate behaviour and personality
change. Episodes of overt HE frequently
result in hospitalisation and may be
predictive of reduced survival.
There is evidence that twice daily
Xifaxan 550 plus lactulose treatment
reduces the risk of a breakthrough HE
episode by 58%. It can also reduce the
risk of hospitalisation attributable to the
condition by 50% when compared to
placebo plus lactulose over six months3.
The rate of adverse and serious adverse
events in patients treated with Xifaxan
550 in this study were similar to those
reported in the placebo group.*
*Bass N, et al NEJM. 2010;362(12)1071--81.
Links Archive Australian Pharmacist February 2014 Australian Pharmacist April 2014 Navigation Previous Page Next Page